Faron Pharma's bexmarilimab demonstrates immune─activating and drug─sensitizing potential in myeloid malignancies
Faron Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel immunotherapies, announced the publication of a new peer-reviewed preclinical study in Scientific Reports, validating the immune-reprogramming and anti-leukemic …